Efficacy and Safety of TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Failed to First-line Treatment: a Prospective, Open-label, Nonrandomized, Multicenter Clinical Trial

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 15 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eltrombopag (Primary) ; Rituximab (Primary) ; Glucocorticoids; Immunoglobulins; Immunosuppressants; Thrombopoietin; Thrombopoietin receptor agonists
Indications Thrombocytopenia
Focus Therapeutic Use

Most Recent Events

03 Jul 2024 Planned End Date changed from 28 Feb 2024 to 28 Feb 2025.
03 Jul 2024 Planned primary completion date changed from 31 Jan 2024 to 31 Jan 2025.
30 Mar 2023 The phase of the trial changed from phase4 to phase 2/3

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight